LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

MannKind Corp

Slēgts

SektorsVeselības aprūpe

3.71 0.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.7

Max

3.72

Galvenie mērījumi

By Trading Economics

Ienākumi

-12M

668K

Pārdošana

-1.8M

77M

P/E

Sektora vidējais

31.091

34.427

Peļņas marža

0.873

Darbinieki

403

EBITDA

8.3M

27M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+129.49% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-142M

1B

Iepriekšējā atvēršanas cena

2.89

Iepriekšējā slēgšanas cena

3.71

Ziņu noskaņojums

By Acuity

44%

56%

139 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. aug. 16:11 UTC

Galvenie tirgus virzītāji

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Target Is Falling Behind Its Peers -- Market Talk

2025. g. 15. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 20:33 UTC

Tirgus saruna

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

2025. g. 15. aug. 20:25 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

2025. g. 15. aug. 20:24 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 20:18 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

2025. g. 15. aug. 19:12 UTC

Tirgus saruna

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

2025. g. 15. aug. 18:32 UTC

Tirgus saruna

Coffee Futures Surge on New Brazilian Frost -- Market Talk

2025. g. 15. aug. 17:33 UTC

Tirgus saruna

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

2025. g. 15. aug. 17:23 UTC

Tirgus saruna
Peļņas

Deere's Earnings Appear to Be Troughing -- Market Talk

2025. g. 15. aug. 16:27 UTC

Peļņas

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. aug. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 15. aug. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

2025. g. 15. aug. 15:52 UTC

Iegādes, apvienošanās, pārņemšana

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

2025. g. 15. aug. 15:36 UTC

Tirgus saruna

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

2025. g. 15. aug. 15:29 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 15:29 UTC

Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 15:28 UTC

Peļņas

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

2025. g. 15. aug. 15:24 UTC

Tirgus saruna

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

2025. g. 15. aug. 15:08 UTC

Tirgus saruna

Applied Materials Is Losing Share in Chips Business -- Market Talk

2025. g. 15. aug. 14:38 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

2025. g. 15. aug. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

2025. g. 15. aug. 14:33 UTC

Iegādes, apvienošanās, pārņemšana

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

129.49% augšup

Prognoze 12 mēnešiem

Vidējais 8.56 USD  129.49%

Augstākais 12 USD

Zemākais 3.5 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

139 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.